Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has made significant strides in developing innovative pain management solutions, particularly focusing on abuse-deterrent formulations. With a commitment to addressing the opioid crisis, Collegium has positioned itself as a pioneer in creating safer alternatives for patients. The company’s flagship product, Xtampza ER, is an extended-release formulation of oxycodone designed to reduce the potential for misuse. Collegium's unique approach to pain management, combined with its robust pipeline of products, underscores its dedication to improving patient outcomes. With a strong market presence and a focus on responsible prescribing, Collegium Pharmaceutical continues to achieve notable milestones in the evolving landscape of pain management therapies.
DitchCarbon Score
How does Collegium Pharmaceutical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Collegium Pharmaceutical, Inc.'s score of 13 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Collegium Pharmaceutical, Inc.'s reported carbon emissions
Collegium Pharmaceutical, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. While no specific climate commitments or initiatives are outlined, it is essential for companies in the pharmaceutical sector to engage in sustainable practices and set measurable targets to reduce their carbon footprint. As the industry increasingly prioritises environmental responsibility, Collegium Pharmaceutical may consider adopting industry-standard climate commitments to enhance their sustainability profile in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Collegium Pharmaceutical, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
